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To the Editor: Campos et al. (1) reported a Zika 
virus (ZIKV) outbreak in Brazil in 2015. This response 
adds complementary data related to the propagation of this 
mosquitoborne disease.
To date, the largest ZIKV outbreak occurred in French 
Polynesia during 2013–2014. The outbreak spread to other 
Pacific Islands: New Caledonia, Cook Islands, Easter Island, 
Vanuatu, and Solomon Islands (2). The origin of introduction 
of ZIKV to French Polynesia remains unknown; introduction 
of ZIKV in New Caledonia was after imported cases from 
French Polynesia (3); introduction to Easter Island was 
suspected to have occurred among attendees of the annual 
Tapati festival, including those from French Polynesia (4). 
The virus was likely transmitted to New Caledonia, Cook 
Islands, and Easter Island when infected travelers from 
French Polynesia were bitten by vectors while on the islands. 
Frequent travel between New Caledonia and Vanuatu is likely 
related to the introduction of ZIKV in the latter country.
Phylogenetic studies showed that the closest strain to 
the one that emerged in Brazil was isolated from samples 
from case-patients in French Polynesia and spread among the 
Pacific Islands (1); both strains belong to the Asian lineage. 
It has been assumed that ZIKV was introduced to Brazil 
during a World Cup soccer competition in 2014 (5), although 
no ZIKV-endemic Pacific countries competed. However, in 
August 2014, the Va’a World Sprint Championship canoe 
race was held in Rio de Janeiro, Brazil. Four Pacific countries 
(French Polynesia, New Caledonia, Cook Islands, and Easter 
Island) in which ZIKV circulated during 2014 had teams 
engaged in this contest in several categories. These data 
combined with phylogenetic studies by Zanluca et al. (5) 
suggest that ZIKV introduction in Brazil may have been a 
consequence of this event. In areas where potential vectors 
are present, vigilance should be enhanced to detect imported 
cases of ZIKV, and laboratory capacity to confirm suspected 
ZIKV infections should be strengthened.
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To the Editor: Since 2014, many cases of urogeni-
tal schistosomiasis acquired in Corsica, France, have 
been described (1–4). The infections, which all occurred 
in persons who had bathed in the Cavu River in 2011 or 
2013, represent the first cases of autochthonous Schisto-
soma haematobium infection acquired in Europe since the 
last reported case in Portugal in 1965 (5). In June 2014, 
France established a screening program for persons re-
porting exposure to the Cavu River during 2011–2013. By 
March 2015, a national surveillance journal had reported 
110 autochthonous urogenital schistosomiasis cases in 
residents of France (6).
We describe the diagnostic work-up for and clinical 
management of persons from Italy who reported bathing 
in the Cavu River at least once during 2011–2014. All of 
the patients had requested screening after learning of the 
risk for acquiring schistosomiasis after freshwater expo-
sure in Corsica. Exclusion criteria for the study included 
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residence in or travel to a country where schistosomiasis 
is endemic.
At least 3 months after their last exposure to the Cavu 
River, each participant had a filtered terminal urine sample 
and a serum sample tested for schistosomiasis. Different 
commercial tests were used, depending on local availabil-
ity: 3 different ELISAs and an indirect immunofluorescent 
antibody test (IIFAT). All serum samples were tested in 
parallel in a laboratory in Florence, Italy, by using 2 West-
ern blots (WBs): a Schistosoma WB IgG kit containing 
antigens from adult S. mansoni worms and a second kit 
containing S. mansoni and S. haematobium antigens from 
a crude adult extract (LDBio Diagnostics, Lyon, France).
Confirmed urogenital schistosomiasis was defined by 
confirmation of S. haematobium eggs in urine by microsco-
py, positive WB result, or both. Probable urogenital schis-
tosomiasis was defined by positive serologic test results. 
Possible urogenital schistosomiasis was defined by signs 
or symptoms suggestive of schistosomiasis (i.e., urogenital 
symptoms), eosinophilia (>0.4 × 109 cells/L of blood), or 
both (7). All participants who met the case definition re-
ceived 1 oral dose of praziquantel (40 mg/kg).
Forty-three persons were consecutively enrolled dur-
ing January 2014–January 2015; of these, 15 (34%) had 
confirmed (6 patients), probable (2 patients), or possible 
(7 patients) urogenital schistosomiasis (Table). Of these 15 
patients, 7 (47%) reported repeat visits to Cavu River over 
a period of at least 2 years. The mean eosinophil count was 
295 (range 40–1,540) cells/μL of blood; 6 (40%) patients 
had eosinophilia. Genitourinary symptoms were reported 
by 7 (47%) patients, and blood was detected by dipstick in 
the urine of 1 patient. Schistosoma eggs were not found in 
any urine samples.
Schistosomiasis screening has been suggested for per-
sons with exposure to the Cavu River (6); however, clini-
cal history and clinical evaluation alone and eosinophilia, 
have low sensitivity for the diagnosis of urogenital schisto-
somiasis (7,8). Asymptomatic infection has been reported 
in 25%–36% of persons with travel-associated schistoso-
miasis, and eosinophilia was present in 50% of the patients 
(7,8). In screenings in France, only 27% of schistosomia-
sis-positive patients reported genitourinary symptoms (6).
For the diagnosis of urogenital schistosomiasis, serolog-
ic testing is more sensitive than detection of eggs in urine, 
particularly in mild infections (7–9). Many asymptomatic 
family members of the index case-patients who acquired in-
fection in Corsica tested positive only by serologic testing 
(1–4). However, commercial serologic tests for schistoso-
miasis have low sensitivity (9). Kinkel et al. (9) showed that 
sensitivity of an IIFAT and 3 ELISAs for S. haematobium 
ranged from 21.4% to 71.4%. In the Corsica outbreak, sero-
logic testing may be even less sensitive because of the hybrid 





Table. Demographic, epidemiologic, clinical, and laboratory data for 15 patients with urogenital schistosomiasis acquired after bathing 











ova ELISA‡ IFAT WB§ 
Infection 
definition 
12/M 2012 Urgency to urinate 210 3 Neg Neg: T1, T2 ND Neg: WB1, WB2 Possible 
12/M 2012 None 550 3 Neg Neg: T1, T2 ND Neg: WB1, WB2 Possible 
68/M 2012 Acute prostatitis 190 3 Neg Neg: T1, T2 ND Neg: WB1, WB2 Possible 
5/M 2011, 2012, 
2013 
None 560 3 Neg Neg: T2 ND Neg: WB1, WB2 Possible 
64/M 1990–2013 Macroscopic 
hematuria, 
hematospermia 
140 1 Neg Pos: T1; 
Neg: T2 
ND Neg: WB1, WB2 Probable 
57/M 1997, 1998, 
2006–2014 
None ND 1 Neg Neg: T1, T2 ND Neg: WB1, WB2 Possible 




1,540 1 Neg Pos: T1; 
Neg: T2 
ND Neg: WB1, WB2 Probable 
37/M 2013 None 380 1 Neg ND Neg Neg: WB1; Pos: 
WB2 
Confirmed 
54/M 2011 None 110 1 Neg ND Neg Neg: WB1; Pos: 
WB2 
Confirmed 
60/F 2014 None 190 1 Neg ND Neg Neg: WB1; Pos: 
WB2 
Confirmed 
58/M 2011, 2012, 
2013 
None 400 1 Neg ND Neg Neg: WB1; Pos: 
WB2 
Confirmed 
11/F 2011, 2012, 
2013 
Vaginal discharge 500 3 Neg ND Neg Neg: WB1; Pos: 
WB2 
Confirmed 
39/M 1980–2013 Urolithiasis 40 3 Neg ND Neg Neg: WB1, WB2 Possible 
29/M 2014 Hematospermia 130 4 Neg ND Neg Neg: WB1, WB2 Possible 
10/M 2011 None 437 1 Neg ND Neg Neg: WB1, WB2 Possible 
*Only 1 patient, the 10-year-old male, had microscopic hematuria. IIFAT, indirect immunofluorescent antibody test; ND, not done; Neg, negative; Pos, 
positive; WB, Western blot. 
†Absolute cell count. 
‡T1 indicates the ELISA used in Udine and Brescia, Italy, and T2 indicates the ELISA used in Negrar, Italy. 
§WB1 contained Schistosomiasis mansoni soluble antigens; WB2 contained S. haematobium plus S. mansoni soluble antigens. 
 
nature of the schistosoma (S. haematobium/S. bovis) (6). In 
our study, only 2 patients had positive ELISA results. Com-
binations of >2 serologic tests can markedly increase testing 
sensitivity to almost 78.6% (9).
Sulahian et al. (10) found that a WB containing S. 
mansoni antigens had 89.5% sensitivity and 100% specific-
ity for S. mansoni. In our study, no patients with urogenital 
schistosomiasis tested positive by WB containing S. man-
soni antigens, but 6 patients tested positive by WB contain-
ing S. haematobium antigens.
In mild infections, the absence of schistosoma antibod-
ies cannot exclude a diagnosis of urogenital schistosomia-
sis (7). Therefore, we provided treatment to patients with 
possible urogenital schistosomiasis; our decision to treat 
these patients considered the tolerability of praziquantel 
and the possible severe genitourinary complications of un-
treated infections (e.g., bladder carcinoma, infertility).
Our findings suggest that a sensitive screening strategy 
for urogenital schistosomiasis consists of a patient’s travel 
history (exposure in multiple years), clinical history (any 
new genitourinary complaints after freshwater exposure), 
eosinophil count, and serologic testing. Because of the fail-
ure of commercial ELISA and IIFAT methods, we empha-
size that a WB containing S. haematobium antigen should 
also be used for screening.
Of note, a confirmed urogenital schistosomiasis case 
acquired after a single exposure in 2014 was never reported 
(1–4,6). The risk for delayed diagnosis of this insidious, ne-
glected disease, which has recently reappeared in Europe, 
must be reduced. To accomplish this, information regard-
ing the risk for schistosomiasis after freshwater exposure 
in Corsica must be disseminated to physicians worldwide.
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